Evotec Reports Good Progress in Product Development in Treatment-Resistant Depression in its Alliance with Roche
Successful completion of first-in-man study with EVT 103
Evotec AG announced two positive aspects that strengthen its integrated product development in treatment-resistant depression in its strategic alliance with Roche. Evotec AG completed the clinical part of the first Phase I study with its NR2B-selective NMDA receptor antagonist EVT 103. EVT 103 is a small molecule drug candidate intended for oral use in conditions such as treatment-resistant depression, but potentially also other CNS indications.
The first-in-human Phase I study was a double-blind, placebo-controlled, randomised ascending dose study in 72 healthy young male subjects. The endpoints of the study were safety, tolerability and pharmacokinetic profile after oral single and multiple dose administration. In addition, the effect of food on the pharmacokinetics of EVT 103 was investigated. The compound was safe and very well tolerated, with excellent bioavailability and only a minimal effect of food on the kinetic profile.
In addition, for its NMDA receptor antagonist EVT 101, which is the lead compound in the strategic alliance with Roche in treatment-resistant depression, the FDA has allowed Evotec to proceed with the initiation of a Proof-of-Concept study. The study will start recruiting patients in Q2.
"We are glad that we received positive feedback from the FDA regarding the toxicology and safety aspects of the planned Proof-of-Concept study with EVT 101. In addition, the Phase I results of EVT 103 now make this a very strong programme for a clinical product development in treatment-resistant depression", said Dr Werner Lanthaler, Chief Executive Officer of Evotec.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Ablynx reports phase II dara for ALX-0081 in high risk ACS patients undergoing a PCI procedure

A further advance in super-resolution fluorescence microscopy - Fast even at the nanometer level
U.S. National Science Advisory Board for Biosecurity (NSABB) recommends Science to publish only an abbreviated version of a H5N1 research report - Science Editor-in-Chief Bruce Alberts on Publication of H5N1 Avian Influenza Research
Novartis Phase III study shows once-daily NVA237 is superior to placebo and similar to tiotropium in improving lung function in COPD - GLOW2 study shows NVA237 provides superior 24-hour bronchodilation to placebo (p
Einstein researchers find molecular structure of key fluorescent proteins

A medical device for safe growth of neural stem cells using nanotechnology
